Copenhagen, Denmark

Zealand Pharma

Danish biotechnology company that describes itself as focused on medicines for obesity and metabolic health. It co-develops petrelintide, an investigational amylin analogue, with Roche. It licensed survodutide, an investigational glucagon/GLP-1 dual agonist, to Boehringer Ingelheim and is eligible for royalties and milestone payments on it. Neither drug is approved.

Petrelintide partnership with Roche

Zealand Pharma and Roche entered an exclusive collaboration and licence agreement in 2025 to co-develop and co-commercialise petrelintide, an amylin analogue, for overweight and obesity. Roche stated upfront payments totalling $1.65 billion ($1.4 billion due at closing and $250 million over the first two anniversaries) and up to $5.3 billion in total potential consideration.[src]

Phase 3 program for petrelintide

On 22 September 2026 Zealand Pharma announced the start of the Phase 3 ZUPREME-3, ZUPREME-4 and ZUPREME-5 trials of petrelintide, with about 7,000 participants in total (about 3,900, 600 and 2,500 respectively). The programme is run with Roche. Petrelintide is investigational.[src]

Survodutide royalties

Zealand Pharma stated on 28 April 2026 that survodutide is licensed from Zealand to Boehringer Ingelheim, which is solely responsible for its global development and commercialisation, and that Zealand is eligible for high single-digit to low double-digit percentage royalties on global sales and EUR 315 million in potential outstanding milestone payments.[src]